Enteropathic Spondyloarthritis: From Diagnosis to Treatment

Rosario Peluso, Matteo Nicola Dario Di Minno, Salvatore Iervolino, Francesco Manguso, Giuseppina Tramontano, Pasquale Ambrosino, Carmela Esposito, Antonella Scalera, Fabiana Castiglione, and Raffaele Scarpa

1 Rheumatology Research Unit, University Federico II, 80131 Naples, Italy
2 Department of Clinical and Experimental Medicine, University Federico II, 80131 Naples, Italy
3 Regional Reference Center for Coagulation Disorders, University Federico II, 80131 Naples, Italy
4 Complex Operating Unit of Gastroenterology, AORN “A.Cardarelli,” Via Sergio Pansini 5, 80131 Naples, Italy
5 Gastroenterology Research Unit, University Federico II, 80131 Naples, Italy

Correspondence should be addressed to Rosario Peluso; rosario.peluso2@unina.it

Received 19 October 2012; Accepted 25 March 2013

1. Introduction

Enteropathic arthritis (EA) is a spondyloarthritis (SpA) which occurs in patients with inflammatory bowel diseases (IBDs) and other gastrointestinal diseases. Diagnosis is generally established on the medical history and physical examination. It was, generally, made according to the European Spondyloarthropathy Study Group (ESSG) criteria. Rheumatic manifestations are the most frequent extraintestinal finding of IBD with a prevalence between 17% and 39%, and IBD is associated, less frequently, with other rheumatic disease such as rheumatoid arthritis, Sjogren syndrome, Takayasu arteritis, and fibromyalgia. Although the pathogenesis of EA has not been plainly clarified, the most popular theory supposes that joint inflammation occurs in genetically predisposed subjects with bacterial gut infections, provided an important evidence for a possible relationship between inflammation of the gut mucosa and arthritis. The management of patients with EA requires an active cooperation between the gastroenterologist and rheumatologist.

2. Classification Criteria

Diagnosis is generally established on the medical history and physical examination, because at present no “gold standard” criteria is available for the diagnosis of EA. Thus, being the SpA a group of distinct diseases with similar clinical features and a common genetic predisposition, the diagnosis...
of EA was, generally, made according to the European
Spondyloarthropathy Study Group (ESSG) criteria [17]. In
fact, IBD is a criterion of SpA; thus, patients with IBD
presenting with inflammatory back pain and/or synovitis
(predominantly of the lower limbs) are diagnosed as having
spondyloarthropathy. These criteria, although they are not
defined for diagnostic purposes, may be a useful guide for the
clinician in the identification of patients with EA. Moreover,
the ESSG criteria, designed to be applicable without radiolog-
ic examination and laboratory testing, have good sensitivity
(86%) and specificity (87%), at least in established disease.

3. Epidemiology

The results from epidemiologic studies on AE have been
influenced by several factors, including the lack of validated
sets of diagnostic criteria, the frequency of IBD in different
graphic areas, the age cut-off and case definition, and
different study designs. The incidence and prevalence of IBD
in Western Countries is estimated to be 6-15/100,000 and 50-
200/100,000, respectively, for CD, and 8-14/100,000 and 120-
200/100,000, respectively, for UC [18].

Rheumatic manifestations are the most frequent extraintes-
tinal manifestation in IBD patients with a prevalence ranging between 17% and 39% [19, 20]. Interestingly, articular
alterations can be diagnosed before, simultaneously, or after
the diagnosis of IBD. The joint involvement observed in
IBD is usually classified in two subsets: axial (including
sacroiliitis with or without spondylitis) and peripheral. The
axial involvement is found to be present in 2%-16% of IBD
patients, with a higher prevalence in CD patients than in UC
ones. Moreover, the prevalence of sacroiliitis (asymptomatic
and symptomatic) is between 12% and 20% and association
with HLA-B27 ranged from 3.9% to 18.9% [19]. Recently,
some studies showed that the prevalence of axial joint
involvement was higher than those reported previously, as
already described by Scarpa et al. in 1992 [21]. In fact, in
these studies, based on the ESSG criteria for SpA [17], the
authors detected a frequency ranging between 17%-39% for
spondylitis and 30%-36% for sacroiliitis [20, 22, 23].

The peripheral involvement is a common complication in
both CD and UC and its prevalence has been reported in a
wide range (0.4%-34.6%) of patients with IBD. It is reported
to be more frequent in CD than UC (20% and 10%, resp.) [24]
and it predominantly affects the joints of the lower limbs [25].
Women show more frequently a peripheral joint involvement,
whereas men tend to have an axial involvement [26, 27].

Interestingly, potential risk factors for arthritis in IBD
patients are active bowel disease, family history of IBD,
appendectomy, cigarette smoking, and the presence of others
extraintestinal manifestations, such as erythema nodosum or
pyoderma gangrenosum [28-31].

4. Pathogenesis

Although the pathogenesis of EA has not been plainly
clarified, the observation that joint inflammation occurs in
genetically predisposed subjects with bacterial gut infections

provided an important evidence for a possible relationship
between inflammation of the gut mucosa and arthritis. At the
end of the 80s, some authors described that more than two-
thirds of patients with SpA showed microscopic inflammatory
changes of gut mucosa without clinical signs of gastroin-
testinal disease [32-35]. In 2000, Scarpa et al. described
microscopic lesions of gut mucosa in PsA patients without
bowel symptoms, also when mucosa appeared macroscopi-
cally normal, suggesting a pathogenetic link between joints,
gut and skin in PsA patients [36].

Current theories provide, in genetically predisposed
subjects, an aberrant migration of intestinal lymphocytes
or macrophages from inflamed gut mucosa to joints, in
which an important role was played by gut bacteria. In fact,
a dysfunctional interaction between the mucosal immune
system and gut bacteria could result in an abnormal state
of immunological tolerance toward flora by alterations in
mucosal effector cells or by affecting regulatory cells [37]. A
significant evidence for the pathogenetic role of gut bacteria
in the pathogenesis of SpA is derived from animals models.

In details, in the HLA-B27/human β2-microglobulin
transgenic rat model, a high copy number of the transgene
is necessary to induce an SpA like disease, characterized
the development of arthritis (sacroiliitis, spondylitis, and
peripheral arthritis) and extra-articular manifestations (pso-
riasiform skin, nail lesions, and enterocolitis). In addition,
these rats do not develop joint, skin, and gut inflammation
when kept in germ-free conditions, reflecting the interplay
between predisposing genes and gut bacteria [38].

In this complex scenario, genetic factors play a predis-
posing role while environmental factors, such as infectious
agents, may play a causative role.

Among the genetic factors, HLA-B27 has the strongest
genetic association with SpA and in particular with anky-
losing spondylitis (AS) [39]. This association is reported
in more than 90% of cases [40]. Also spondylitis in IBD
is associated with the presence of HLA-B27, however, in
lower frequencies than in AS (30%-80%) [24, 41]. Pure
asymptomatic sacroiliitis in CD is not strongly associated
with HLA-B27 and a very recent study indicates a prevalence
of 7% [42]. In 2000, Orchard et al. described an association
with HLA-DR0103, B35, and B27 in type 1 peripheral arthritis
and neither B27 nor DR4 associations were observed in type
2 arthritis [43].

In order to describe the role of HLA-B27 in the pathogen-
esis of EA, different theories have been proposed.

One theory suggests that HLA-B27-expressing macro-
phages expose specific bacterial antigens that may activate
CD4+ T-cells with their migration from gut to joint with
development of arthritis [44-46]. Another theory proposes
that homology between HLA-B27 sequences and bacterial
antigens may activate T-cell and inflammation by antigen
mimicry mechanism [47-49]. Finally, the most recent theory
is based on the endoplasmic reticulum stress: under normal
conditions, the peptide-loaded HLA class I heavy chain binds
the β2-microglobulin (β2m) in the endoplasmic reticulum. The
folding process of the HLA-B27 heavy chain is slower
than that of other HLA alleles thus leading to the generation
of misfolded chains. Misfolded chains are usually removed
in the endoplasmic reticulum, but in certain conditions, such as viral infection, they accumulate thus activating the protein BiP, the endoplasmic reticulum-unfolded-protein-response (UPR) and the nuclear factor κB (NFκB), which play a critical role in the induction of inflammation [50]. Data suggest that deposition of β2m, caused by the high dissociation rate between HLA-B27 heavy chain and β2m, occurring within synovial tissue, may lead to the initiation of chronic inflammation [51, 52].

Other HLA genes have been associated with SpA in IBD: HLA-DRB10103, HLA-B35, HLA-B24 in type 1 peripheral arthritis, and HLA-B44 in type 2 peripheral arthritis [43]. Moreover, Mielants et al. showed an association between HLA-Bw62 and chronic gut lesions associated with a family history of AS and CD, with markers of inflammation, reduced axial mobility, presence of sacroiliitis, destructive joint lesions, and a diagnosis of AS [53].

Further confirming the relevance of HLA-B27 in the pathogenesis of enteroarthritis, Hammer et al. studied transgenic rats overexpressing HLA-B27 molecule. These rats developed a multisystemic inflammatory disease that had several clinical and histopathological similarities to SpA and IBD [54]. An important finding was that these rats did not develop joint or gut inflammation when they were in a germ-free environment [55]. This result supports the theory of the participation of microorganisms in the pathogenesis of these diseases.

In humans with reactive arthritis, following Yersinia enterocolitica, Shigella spp. or Salmonella enteritidis and typhimurium infection, bacterial antigens have been detected in joints [56–59]. Later studies further confirmed this evidence [60–62]. Other molecular studies found similarities between Klebsiella nitrogenase and HLA-B27 and between Klebsiella pullulanase and collagen fibers types I, III, and IV. Interestingly, elevated levels of antibodies against Klebsiella and collagen fibers types I, III, IV, and V were detected in patients with CD and AS [63].

In addition to HLA-B27, other genes have been identified as being related to SpA and IBD. In fact, several common genetic predispositions between SpA and IBD were identified, of which the association with IL-23R polymorphisms is most prominent [64]. The functional role of IL-23 receptor polymorphisms remains unclear, the fact that IL-23 signaling plays a critical role in the Th17-mediated inflammation indicates that Th17 cells may represent a common pathogenetic mechanism in both IBD and SpA [65]. The first susceptibility gene that has been identified for CD is CARD15 (or NOD2). Variants within this gene increase the risk for CD by threefold for heterozygous and fortyfold for homozygous individuals. An association was also found in SpA patients between the carriage of CARD15 variants and the development of chronic subclinical gut inflammation [66]. Although CARD15 mutations do not seem to predispose to arthritis, it might confer a risk towards the development of (sub) clinical gut inflammation in SpA patients, rendering these patients more disposed to develop IBD. A CARD15-mediated NFκB-dependent inflammatory reaction might be an important pathogenetic process within the joints [67]. The protein is expressed in joint tissue, and bacterial cell wall components have been demonstrated in synovium of SpA patients, supporting the idea that CARD15 can locally trigger inflammation [68]. Recently, additional shared associations between SpA and IBD were found at chromosome 1q32 near KIF21B (genome-wide significant), STAT3, IL-12B, CDKAL1, LRRK2/MUC19, and chromosome 13q14 (experiment-wise association). As the genes IL-23R, STAT3, and IL-12B all influence Th17 lymphocyte differentiation/activation, this provides further evidence implicating the Th17 lymphocyte subset in the pathogenesis of SpA [65].

In addition to genetic susceptibility, an important role was also been given to the environmental factors in triggering the onset of disease. In fact, bacterial gut infections such as Yersinia enterocolitica, Salmonella typhimurium, Campylobacter jejuni, and Shigella spp may cause joint inflammation in genetically predisposed patients. Given the prototypical link between certain bacterial infections and the onset of reactive arthritis, several studies have aimed to assess the role of intestinal flora in disease progression, as well as the resulting changes in mucosal response [69]. On the basis of these observation, the possible pathways involved in joint and gut inflammation in EA may be the following: in the acute phase of inflammation, bacterial infections can cause acute intestinal inflammation. Certain bacteria may survive intracellularly in macrophages that can traffic to the joint and cause an arthritis in a genetically predisposed host. Proinflammatory cytokines such as TNF and IL-23 are produced locally, with Paneth cells being the most important producers of IL-23 in the intestine. This expression can activate innate immune cells (NK) to produce IL-22 that may help control inflammation at mucosal sites. Otherwise, damage and pathogen associated molecular pattern molecules (DAMPs and PAMPs) and cellular stretch might promote initiation of joint inflammation. In the transition phase, acute intestinal and articular inflammation can be sustained due to defective immune regulation by TREG cells, or by ER stress, whereas iNKT cells act as regulators to control inflammation. Proangiogenic factors such as PlGF can lead to aberrant neovascularisation. These events may lead to chronicity, further enhanced or maintained by repetitive cellular stress. In this stage, stromal cells become more important, as targets for proinflammatory cytokines (Figure 1).

4.1. Clinical Pattern. The joint involvement observed in IBD is classified in two subsets: peripheral and axial (including sacroiliitis with or without spondylitis) [24]. There may be other periarthritis manifestations such as enthesopathy, dactylitis, tendonitis, periostitis, clubbing, granulomatous lesions (in joints and bones), osteoporosis, and osteomalacia [70].

The arthritic manifestations of IBD are divided into different clinical subsets: peripheral and axial joint involvement (including sacroiliitis with or without spondylitis). Peripheral arthritis is the most frequent finding in both CD and UC and may occur with a frequency ranging between 17% and 20% [24], and it is more common in CD [71]. The peripheral arthritis equally affects both the sexes and the onset age is between 25 and 45 years. It can diagnosed before,
The axial involvement is more common in patients with CD (5%-22%) than in those with UC (2%-6%) [19]. Its onset precedes the enteritis and its course is not related to it [73]. Both progressive ankylosing spondylitis and sacroiliitis (sometimes asymptomatic) may occur. Ankylosing spondylitis (AS) affects the vertebral column by progressive ankylosis of the vertebral and the sacroiliac joints. The clinical course of AS in IBD is similar to idiopathic AS, and disease progression leads to increasing immobility of the spine resulting in ankylosis (bamboo spine) [73].

Radiological examination of the affected joints basically shows the absence of erosions as well as of osteoporosis or joint narrowing. The use of joint scintigraphy is helpful, as, in some cases, this technique shows the hyper accumulation of the tracer even in presence of negative radiological findings, particularly on a sacroiliac level. Recently, some studies have revealed that the axial subset incidence is higher than the previously reported one, as formerly described by our research team in 1992 [21]. In fact, in these studies, based on the ESSG SpA criteria [17], the authors have detected a prevalence between 10% and 25% of spondylitis, and between 30% and 36% of sacroiliitis [20, 22, 23]. A complication of the axial subset in patients with IBD is the development of sclerotic erosive lesions in the adjacent vertebral bodies [74] or aseptic spondylodiscitis, also defined as Andersson lesions (ALs) [75], whose diagnosis is often delayed, particularly in patients simultaneously, or after the diagnosis of IBD. It is generally acute and it reaches the symptoms apex within 48 hours. The clinical picture is that of an asymmetric monooarthritis which affects especially the large joints of the lower limbs, less frequently those of the upper limbs. In general, the small joints involvement is more typical of CD. The course is episodic and recurrent, with spontaneous reduction of symptoms within about 6 months; a small percentage tends to become chronic. In addition, exacerbations are characterizing, connected with the activity stages of the inflammatory bowel disease. The nature of arthritis is generally related to the extension and severity of intestinal involvement, a more evident aspect of the UC, and to the incidence of extraintestinal complications, such as uveitis, stomatitis, erythema nodosum, and pyoderma gangrenosum. A stable reduction of arthritis is often observed after a colectomy. In 1998, Orchard et al. [26] distinguished two subtypes of peripheral arthritis: type 1, the pauciarticular form (involving fewer than 5 joints), acute and self-limited, which may precede the diagnosis of IBD, generally running parallel to the intestinal disease; type 2, the polyarticular form (involving 5 or more joints), with symptoms lasting for months or years, independently from inflammatory bowel disease. More recently, Smale et al. have shown another type of peripheral arthritis (type 3) that includes patients with both axial and peripheral forms [72].
having an insidious onset and nonspecific symptoms [76]. Our research group has recently investigated the occurrence and the clinical features of ALs arthritis in EA, detected by magnetic resonance imaging, an imaging technique usually accepted to evaluate the axial and peripheral involvement of SpA [77–79], and we found an high prevalence of this lesion among EA patients (30.55%), confirming that ALs are an important characteristic aspect of SpA. In particular, we found a high prevalence in patients with axial and peripheral subset (31.82%) suggesting that ALs could be a characterizing feature of the overlap subset [57]. Furthermore, in contrast with what was reported for ankylosing spondylitis [80] and psoriatic arthritis [81], the occurrence of these lesions in patients with UC and CD was earlier and often asymptomatic [82] (Table 1).

5. Other Rheumatic and Extra-Articular Manifestations

IBD is associated, less frequently, with other rheumatic disease such as rheumatoid arthritis [83], Sjogren syndrome [84], Takayasu arteritis [85, 86], and fibromyalgia [87].

Enthesitis, dactylitis, and buttock pain are a part of EA and their occurrences are not different from the other SpA. The extra-articular manifestations are characterized by acute anterior uveitis, aortic insufficiency, and cardiac conduction disturbances with a frequency of 25%, 4%–10%, and 3%–9%, respectively. They seem to be related to disease duration, axial joint involvement, and with HLA-B27 positivity. Skin lesions occur in 10%–25% of the patients and are characterized by erythema nodosum, coinciding with exacerbations of the gut inflammation and thus tends to occur in patients with active peripheral synovitis [26], and pyoderma gangrenosum, not related to gut inflammation, which is reported in 2.2% of UC patients and 1.5% of CD patients with a female predominance [88, 89] and is considered to be the most severe skin manifestation in IBD.

Recently, our research group has investigated the occurrence of chronic autoimmune thyroiditis or Hashimoto’s thyroiditis (HT) in EA patients [90]. HT is known to be an extraintestinal complications of IBD and the increased prevalence of thyroid antibodies in ulcerative colitis patients has been reported to range from 0.82% [91] to 3.7% [92]. Our results show that HT occurs more frequently in EA patients. In details, TPOAbs positivity occurs more frequently in patients with a long disease duration and active rheumatic disease than in the other patients suggesting a possible relationship between the maintenance of the inflammatory process in EA patients and the positivity of TPOAbs. Furthermore EA patients affected by thyroiditis show a peripheral involvement, with a significantly high prevalence of polyarticular joint involvement [90].

6. Cardiovascular Disease and EA

Several literature data clearly suggest that subjects with IBD, as well as those with spondyloarthritides, show an increased thrombotic risk. Significantly less data are available about EA subjects.

Both venous and arterial thrombosis risks have been studied in IBD subjects. Many reports document an increased risk of venous thrombotic events in patients with IBD while the risk of arterial thrombotic events has been less well characterized [93]. However, some studies described an increased cardiovascular (CV) risk in this clinical setting [94]. Common carotid artery intima-media thickness (IMT) is significantly higher in IBD subjects as compared with controls [95]; so IBD seems to be a risk factor for cardiovascular and cerebrovascular events [96–99] even in young patients. Premature subclinical atherosclerosis with high-density lipoprotein cholesterol values, high IMT, and reduced flow-mediated dilation (FMD) has been reported in children with inflammatory bowel disease [100]. Moreover, a frequent occurrence of metabolic syndrome (MS) was documented in IBD, especially in UC [101]. Also the risk of hyperhomocysteinaemia is significantly higher in IBD patients when compared with controls [102–104], and an increased prevalence of hepatic steatosis, which is
a recognized predictor of arterial and venous thrombosis, has been found both in the IBD population [105] and in subjects with enteropathic arthritis [106, 107].

Female gender seems to further increase CV risk among IBD patients [108]. A retrospective cohort study revealed that women over the age of 40 years with IBD are at increased risk of myocardial infarction. In contrast, this report showed that men with IBD do not share the same risks for arterial thrombotic events. The study also revealed that IBD patients have a significant risk of acute mesenteric ischemia when compared with controls [93]. Accordingly, another study explored comorbidities in IBD patients, showing an increased prevalence of coronary artery disease (OR 1.883, $P = 0.001$) with a higher risk in female patients (OR 1.6, $P = 0.014$) [108].

Whereas many studies are consistent about the increased risk of arterial thrombotic events, some studies have failed to demonstrate an increased CV risk in IBD subjects [109, 110]. Interestingly, the retrospective study by Ha et al. [93] did not find an increased risk of coronary artery disease (CAD) in IBD subjects but showed a high prevalence of hypertension and hyperlipidemia. Conversely, another retrospective study showed that IBD patients had an increased risk of CAD but lower rates of the traditional risk factors for CAD (obesity, diabetes mellitus, hypertension, and hyperlipidemia) [94]. Furthermore, a recent meta-analysis [111] (including 11 studies for a total of 14,065 patients) was not able to demonstrate an increased cardiovascular mortality in the IBD population. Anyway, the authors themselves found some limitations that can explicate these results, such as the younger age, the short duration of followup, the protective role of lower BMI and lipid levels, or lower cigarette use of these patients. Thus, further properly designed studies are needed to address these issues.

An increased CV risk has been documented also in subjects with spondyloarthritides [112, 113] and other systemic inflammatory diseases, such as rheumatoid arthritis, Sjogren syndrome, and systemic lupus erythematosus [114, 115]. Both in psoriatic arthritis and in AS, an impaired vascular flow-mediated dilation and carotid intima-media thickening [116–118] have been found. In AS the coronary flow reserve and the left ventricular diastolic function are impaired and these findings are positively correlated with inflammatory indices, such as C-reactive protein [119]. However, other studies do not confirm the finding of an increased CV risk in AS subjects [120, 121].

Despite the common inflammatory pathogenesis and the evidences of increased CV risk both in IBD and in SpA, there are no literature data on the CV risk in EA patients.

In addition, according to recent data [122] suggesting a strict correlation between arterial and venous thrombosis, it is interesting to highlight that a series of studies are consistent with the hypothesis of an increased venous thrombosis risk in IBD subjects [93, 123–125]. Patients with IBD have an increased risk of venous thrombotic events. Recently, a history of Venous Thrombo Embolism (VTE) has been documented in 22.5% of IBD patients, who reported a total of 21 thromboembolic manifestations, including 15 deep venous thrombosis (DVT), 3 thrombophlebitis, 2 thrombosis of the superficial femoral artery, and 1 thrombosis of the central retinal vein. A disregulation of the haemostatic system was also described, regardless the occurrence of thromboembolic events. Thrombocytosis was observed in 33% of IBD patients, hyperhomocysteinemia in 26.7%, increased D-dimer values in 25.3%, elevated C3 in 15.4%, and resistance to activated protein C (APCr) in 5.6% [93]. This study further confirms a thromboembolic tendency in IBD patients and also suggests the occurrence of a disregulation of the hemostatic system.

Many other reports show an hemostatic disequilibrium, mainly in the active form of IBD, documenting higher levels of procoagulant factors (XI, XII, X, V), prothrombin and side-products of prothrombin cleavage and, on the other hand, lower or normal levels of anticoagulant factors (protein S, protein C, and antithrombin III) and a reduced activity of the fibrinolytic system [126–131]. Also endothelial dysfunction with impaired NO production has been found in IBD subjects [132, 133]. From 1968 [134] the association between thrombocytosis and IBD is known and later studies found changes in platelet count [103], volume [135] and activation [136] and an increased number of circulating platelet-leukocyte aggregates [137]. Finally, a recent study found that CD and UC patients also have an increased risk of developing pericarditis compared to healthy controls [138].

Overall, given changes in the haemostatic balance, as well as the evidence of an increased IMT both in IBD and in SpA subjects, the evaluation of the CV risk in EA subjects is now mandatory.

### 7. Treatment

The management of patients with EA requires an active cooperation between gastroenterologist and rheumatologist.

The use of corticosteroids and/or DMARDs and/or of anti-TNFα, helpful to contain intestinal inflammation, usually leads also to the reduction of peripheral type I arthritis symptoms, which also well respond to rest, to physiokeistherapy and to intra-articular injections of steroids. On the contrary, the management of types II and III is more complex and they may persist despite the reduction of IBD. Our experience suggests that the majority of patients promptly respond to anti-inflammatory drugs, useful to control joint and entheses inflammation. However, they do not stop the development of joint damage and, at the same time, they may also be responsible for important side effects on the bowel, such as the exacerbation of IBD [139, 140], thus causing the appearance of small intestine and colon ulcers [141]. As a consequence, in order to manage joint symptoms, these drugs are recommended for patients with mild exacerbations but their use should be limited to the lowest effective dose and only for short periods of time.

Sulfasalazine and 5-aminosalicylic acid are often used for the treatment of IBD, being their effectiveness also confirmed for the management of mild peripheral arthritis, particularly in patients with UC [142, 143]. Their effectiveness on CD has not been well proved yet. These drugs have no effect on the evolution of joint damage to severe forms of arthritis and their usefulness in the axial subset is minimal; they do not
seem to prevent the possible onset of intestinal inflammation in patients with SpA [144].

Immunosuppressants such as methotrexate, azathioprine, cyclosporine, and leflunomide show their efficacy in some patients with peripheral arthritis and other extraintestinal components [145–149]. Recently, our team has been studying the efficacy and the tolerability of methotrexate at a dose of 20 mg/week, in patients with peripheral arthritis under UC, and we have shown a rapid and effective reduction of joint symptoms with significant improvement in laboratory parameters and in rates of disease activity [150].

The anti-TNFα, especially infliximab and adalimumab, are showed to be successful in the restraint not only of the intestinal inflammation but also of the joint clinical picture (axial and peripheral), especially in patients with CD; currently, these drugs are widely used to treat enteric arthritis [151]. Etanercept, instead, seems to be effective only to control joint symptoms but not the intestinal ones [152, 153].

Some authors [154–156] have also proposed to use probiotics in order to treat patients with inflammatory bowel disease and arthritis. Probiotics alter intestinal flora and by bacteria, which are able to modulate the immune response by the Toll-like receptor 9 (TLR9), a specific receptor for CpG motifs, mainly shown by bacteria, which are able to modulate the immune response [158].

Finally, in consideration of the high CV risk among IBD patients, common cardiovascular drugs (statins and angiotensin-converting enzyme inhibitors) may have dual potential for preventing or treating coronary artery disease and controlling inflammatory bowel disease [159].

Disclosure

All the authors revised and approved the present version of this paper. No funding and economic support has been received to perform this study. Professor Raffaele Scarpa did not receive specific funding for the preparation of this paper. During the last 5 years, they served on advisory boards and received honoraria and grants for research unrelated to this study. The other authors have nothing to declare.

Authors’ Contribution

Rosario Peluso and Matteo Nicola Dario Di Minno equally contributed to the paper. Rosario Peluso and Matteo Nicola Dario Di Minno had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study design: Rosario Peluso, Matteo Nicola Dario Di Minno, Fabiana Castiglione. Acquisition of data: Salvatore Iervolino, Pasquale Ambrosino, Carmela Esposito, Giuseppina Tramontano, and Antonella Scaler. Analysis and interpretation of data: Rosario Peluso, Matteo Nicola Dario Di Minno, Francesco Manguso, Raffaele Scarpa. Manuscript preparation: Rosario Peluso, and Matteo Nicola Dario Di Minno.

References

[1] M. Leirisalo-Repo, “Enteropathic arthritis, Whipple’s disease, juvenile spondyloarthropathy, and uveitis,” Current Opinion in Rheumatology, vol. 6, no. 4, pp. 385–390, 1994.
[2] A. Orlando, S. Remna, G. Perricone, and M. Cottone, “Gastrointestinal lesions associated with spondyloarthropathies,” World Journal of Gastroenterology, vol. 15, no. 20, pp. 2443–2448, 2009.
[3] R. Smith, “Treatment of rheumatoid arthritis by colectomy,” Annals of Surgery, vol. 76, pp. 515–578, 1922.
[4] J. A. Bargen, R. J. Jackman, and J. G. Kerr, “Complications and sequel of chronic ulcerative colitis,” Annals of Internal Medicine, vol. 3, pp. 335–352, 1929.
[5] P. S. Hench, “Acute and chronic arthritis,” in Nelson’s Loose Leaf of Surgery, G. H. Whipple, Ed., p. 104, Thomas Nelson Sons, New York, NY, USA, 1935.
[6] E. G. Bywaters and B. M. Ansell, “Arthritis associated with ulcerative colitis: a clinical and pathological study,” Annals of the Rheumatic Diseases, vol. 17, no. 2, pp. 169–183, 1958.
[7] J. A. Mc Bride, M. J. King, A. G. Baille, G. P. Crean, and W. Sircus, “Ankylosing spondylitis and chronic inflammatory diseases of the intestines,” British Medical Journal, vol. 2, no. 5355, pp. 483–486, 1963.
[8] V. L. Steinberg and G. Storey, “Ankylosing spondylitis and chronic inflammatory lesions of the intestines,” British Medical Journal, vol. 2, no. 5054, pp. 1157–1159, 1957.
[9] J. S. Stewart and B. M. Ansell, “Ankylosing spondylitis associated with regional enteritis,” Gastroenterology, vol. 45, pp. 263–268, 1963.
[10] B. S. Blumberg, J. J. Bunim, E. Calkins, C. L. Pirani, and N. J. Zvaifler, “Aranomenclature and classification of arthritis and rheumatism (tentative),” Arthritis and Rheumatism, vol. 7, pp. 93–97, 1964.
[11] V. Wright and J. H. M. Moll, Seronegative Polyarthritis, North Holland Publishing Company, Amsterdam, The Netherlands, 1976.
[12] R. H. Puite and H. Tesluk, “Whipple’s disease,” The American Journal of Medicine, vol. 19, no. 3, pp. 383–400, 1955.
[13] J. J. Kelly III and B. B. Weisiger, “The arthritis of Whipple’s disease,” Arthritis and Rheumatism, vol. 6, pp. 615–632, 1963.
[14] J. Friis and A. Svejgaard, “Letter: Salmonella arthritis and HL-A27,” The Lancet, vol. 1, no. 7870, p. 1350, 1974.
[15] K. Aho, P. Ahvonen, and A. Lassus, “Versinia arthritis and related diseases,” in Infection and Immunology in the Rheumatic Diseases, D. C. P. Dumond, Ed., pp. 341–344, Oxford Blackwell, 1976.
[16] J. Braun and J. Sieper, “Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002,” Annals of the Rheumatic Diseases, vol. 61, supplement 3, pp. iii61–iii67, 2002.
[17] M. Dougados, S. van der Linden, R. Juhlin et al., “The European Spondylarthropathy Study Group preliminary criteria for the
classification of spondylarthropathy,” *Arthritis and Rheumatism*, vol. 34, no. 10, pp. 1218–1227, 1991.

[18] J. Cosnes, C. Gower-Rousseau, P. Seksik, and A. Cortot, “Epidemiology and natural history of inflammatory bowel diseases,” *Gastroenterology*, vol. 140, no. 6, pp. 1785–1794, 2011.

[19] C. Salvaneschi and W. Fries, “Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease,” *World Journal of Gastroenterology*, vol. 15, no. 20, pp. 2449–2455, 2009.

[20] N. Turkcapar, M. Toruner, I. Soykan et al., “The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease,” *Rheumatology International*, vol. 26, no. 7, pp. 663–668, 2006.

[21] R. Scarpa, A. del Puente, A. D’Arienzo et al., “The arthritis of ulcerative colitis: clinical and genetic aspects,” *Journal of Rheumatology*, vol. 19, no. 3, pp. 373–377, 1992.

[22] K. de Vlam, H. Mielants, C. Cuvelier, F. de Keyser, E. M. Veys, and M. de Vos, “Spondyloarthritis is underestimated in inflammatory bowel disease: prevalence and HLA association,” *Journal of Rheumatology*, vol. 27, no. 12, pp. 2860–2865, 2000.

[23] P. Wordsworth, “Arthritis and inflammatory bowel disease,” *Current Rheumatology Reports*, vol. 2, no. 2, pp. 87–88, 2000.

[24] T. S. Rodríguez-Reyna, C. Martínez-Reyes, and J. K. Yamamoto-Berghe, “HLA-B27 related arthritis and bowel inflammation—part 2: ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis,” *Journal of Rheumatology*, vol. 12, no. 2, pp. 294–298, 1985.

[25] R. Scarpa, F. Manguso, A. D’Arienzo et al., “Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms,” *Journal of Rheumatology*, vol. 27, no. 5, pp. 1241–1246, 2000.

[26] P. Jacques, D. Elewaut, and H. Mielants, “Interactions between gut inflammation and arthritis/spondylitis,” *Current Opinion in Rheumatology*, vol. 22, no. 4, pp. 368–374, 2010.

[27] P. Jacques and D. Elewaut, “Joint expedition: linking gut inflammation to arthritis,” *Mucosal Immunology*, vol. 1, no. 5, pp. 364–371, 2008.

[28] L. Schlossstein, P. I. Terasaki, R. Bluestone, and C. M. Pearson, “High association of an HL-A antigen, W27, with ankylosing spondylitis,” *The New England Journal of Medicine*, vol. 288, no. 14, pp. 704–706, 1973.

[29] M. A. Brown, K. D. Pile, L. G. Kennedy et al., “HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom,” *Annals of the Rheumatic Diseases*, vol. 55, no. 4, pp. 268–270, 1996.

[30] E. G. Mallas, P. Mackintosh, P. Asquith, and W. T. Cooke, “Histocompatibility antigens in inflammatory bowel disease; their clinical significance and their association with arthropathy with special reference to HLA B27 (W27),” *Gut*, vol. 17, no. 11, pp. 906–910, 1976.

[31] H. Peeters, B. Vander Cruyssen, H. Mielants et al., “Clinical and genetic factors associated with sacroiliitis in Crohn’s disease,” *Journal of Gastroenterology and Hepatology*, vol. 23, no. 1, pp. 132–137, 2008.

[32] T. R. Orchard, S. Thiyagaraja, K. I. Welsh, B. P. Wordsworth, J. S. H. Gaston, and D. P. Jewell, “Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease,” *Gastroenterology*, vol. 118, no. 2, pp. 274–278, 2000.

[33] W. Kuon and J. Sieper, “Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis,” *Rheumatic Disease Clinics of North America*, vol. 29, no. 3, pp. 595–611, 2003.

[34] A. K. H. Mertz, P. Wu, T. Sturniolo et al., “Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles,” *Journal of Immunology*, vol. 164, no. 3, pp. 1529–1537, 2000.

[35] A. Thiel, P. Wu, R. Lauster, J. Braun, A. Radbruch, and J. Sieper, “Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry,” *Arthritis & Rheumatism*, vol. 43, no. 12, pp. 2834–2842, 2000.

[36] R. H. Scaife, B. K. J. Y. Moorhouse, W. L. Warren, and J. B. Harley, “HLA-B27 binding of peptide from its own sequence
[141] H. L. Kaufman, A. H. Fischer, M. Carroll, and J. M. Becker, “Colonic ulceration associated with nonsteroidal anti-inflammatory drugs: report of three cases,” Diseases of the Colon and Rectum, vol. 39, no. 6, pp. 705–710, 1996.

[142] A. S. Dissanayake and S. C. Truelove, “A controlled therapeutic trial of long term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin),” Gut, vol. 14, no. 12, pp. 923–926, 1973.

[143] A. P. Dick, M. J. Grayson, R. G. Carpenter, and A. Petrie, “Controlled trial of sulphasalazine in the treatment of ulcerative colitis,” Gut, vol. 5, pp. 437–442, 1964.

[144] M. B. Ferraz, P. Tugwell, C. H. Goldsmith, and E. Atra, “Meta-analysis of sulfasalazine in ankylosing spondylitis,” Journal of Rheumatology, vol. 17, no. 11, pp. 1482–1486, 1990.

[145] L. Rodríguez-Bores, J. Barahona-Garrido, and J. K. Yamamoto-Furusho, “Basic and clinical aspects of osteoporosis in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 13, no. 46, pp. 6156–6165, 2007.

[146] M. Padovan, G. Castellino, M. Govoni, and F. Trotta, “The treatment of the rheumatological manifestations of the inflammatory bowel diseases,” Rheumatology International, vol. 26, no. II, pp. 953–958, 2006.

[147] F. de Keyser, N. van Damme, M. de Vos, H. Mielants, and E. M. Veys, “Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation,” Inflammation Research, vol. 49, no. 2, pp. 47–54, 2000.

[148] J. Chen and C. Liu, “Methotrexate for ankylosing spondylitis,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD004524, 2004.

[149] H. Haibel, M. Rudwaleit, J. Braun, and J. Sieper, “Six months open label trial of leflunomide in active ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 64, no. 1, pp. 124–126, 2005.

[150] R. Peluso, M. Atteno, S. Iervolino et al., “Methotrexate in the treatment of peripheral arthritis in ulcerative colitis,” Reumatismo, vol. 61, no. 1, pp. 15–20, 2009.

[151] F. van den Bosch, E. Kruithof, M. de Vos, F. de Keyser, and H. Mielants, “Crohn’s disease associated with spondyloarthritis: effect of TNF-α blockade with infliximab on articular symptoms,” The Lancet, vol. 356, no. 9244, pp. 1821–1822, 2000.

[152] H. Marzo-Ortega, D. McGonagle, P. O’Connor, and P. Emery, “Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis,” Annals of the Rheumatic Diseases, vol. 62, no. 1, pp. 74–76, 2003.

[153] S. Iervolino, G. Tramontano, M. Lofrano et al., “Etanercept nel trattamento dell’artrite enteropatica associata a malattia di Crohn: descrizione di un caso clinico,” Reumatismo, vol. 63, supplement 3, p. 125, 2011.

[154] M. G. Neuman and R. M. Nanau, “Inflammatory bowel disease: role of diet, microbiota, life style,” Translational Research, vol. 160, no. 1, pp. 29–44, 2012.

[155] G. R. Veerappan, J. Betteridge, and P. E. Young, “Probiotics for the treatment of inflammatory bowel disease,” Current Gastroenterology Reports, vol. 14, no. 4, pp. 324–333, 2012.

[156] O. Karimi and A. S. Peña, “Probiotics in arthralgia and spondyloarthopathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary,” Revista Espanola de Enfermedades Digestivas, vol. 97, no. 8, pp. 570–574, 2005.

[157] M. Rudwaleit and D. Baeten, “Ankylosing spondylitis and bowel disease,” Best Practice and Research: Clinical Rheumatology, vol. 20, no. 3, pp. 451–471, 2006.